Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 73-98

  D'Souza, Ursula M ^a   Craig, Ian W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

dopamine; expression; polymorphisms; psychiatry; serotonin

Indexed keywords

DOPAMINE; SEROTONIN;

ALLELE; BEHAVIOR DISORDER; BIPOLAR DISORDER; CADAVER; DOPAMINE METABOLISM; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRON; LYMPHOBLAST; MAJOR DEPRESSION; MAMMAL CELL; NEUROIMAGING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN MOTIF; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEROTONIN METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; BEHAVIOR; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENOTYPE; HUMANS; MENTAL DISORDERS; MOLECULAR SEQUENCE DATA; MONOAMINE OXIDASE; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TYROSINE 3-MONOOXYGENASE;

EID: 50649090245     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00904-7     Document Type: Review

References (214)

1. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., Smith C.L., Shafa R., Aeali B., Carnevale J., Pan H., Papageorgis P., Ponte J.F., Sivaraman V., Tsuang M.T., and Thiagalingam S. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 15 (2006) 3132-3145
2. Abdolmaleky H.M., Faraone S.V., Glatt S.J., and Tsuang M.T. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr. Res. 67 (2004) 53-62
3. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., and Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 23 (2003) 2008-2013
4. Albanese V., Biguet N.F., Kiefer H., Bayard E., Mallet J., and Meloni R. Quantitative effects on gene silencing by allelic variation at a tetranucleotide microsatellite. Hum. Mol. Genet. 10 (2001) 1785-1792
5. Anney R.J., Rees M.I., Bryan E., Spurlock G., Williams N., Norton N., Williams H., Cardno A., Zammit S., Jones S., Jones G., Hoogendoorn B., Smith K., Hamshere M.L., Coleman S., Guy C., O'Donovan M.C., Owen M.J., and Buckland P.R. Characterisation, mutation detection, and association analysis of alternative promoters and 5′ UTRs of the human dopamine D3 receptor gene in schizophrenia. Mol. Psychiatry 7 (2002) 493-502
6. Aranyi T., Faucheux B.A., Khalfallah O., Vodjdani G., Biguet N.F., Mallet J., and Meloni R. The tissue-specific methylation of the human tyrosine hydroxylase gene reveals new regulatory elements in the first exon. J. Neurochem. 94 (2005) 129-139
7. Arcos-Burgos M., Lopera F., Rapoport J.L., Pineda D., Castellanos F.X., Konecki D., Bailey-Wilson J., Palacio J.D., and Berg K. Pedigree disequilibrium test (PDT) replicates association and linkage between DRD4 and ADHD in multigenerational and extended pedigrees from a genetic isolate. Mol. Psychiatry 9 (2004) 252-259
8. Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V., and Van Tol H.H. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65 (1995) 1157-1165
9. 4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 46 (1994) 364-373
10. 3 receptor gene in schizophrenia. Mol. Psychiatry 1 (1996) 125-132
11. Balciuniene J., Emilson L., Oreland L., Pettersson U., and Jazin E.E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum. Genet. 110 (2002) 1-7
12. Baron M. Candidate genes and behavioural traits - candidly. Arch. Gen. Psychiatry 56 (1999) 582-583
13. Barr C.L., Feng Y., Wigg K.G., Schachar R., Tannock R., Roberts W., Malone M., and Kennedy J.L. 5′Untranslated region of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Am. J. Med. Genet B Neuropsychiatr. Genet. 105B (2001) 84-90
14. Barr C.L., Xu C., Kroft J., Feng Y., Wigg K., Zai G., Tannock R., Schachar R., Malone M., Roberts W., Nothen M.M., Grunhage F., Vanderbergh D.J., Uhl G., Sunohara G., King N., and Kennedy J.L. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder. Biol. Psychiatry 49 (2001) 333-339
15. Battersby S., Ogilvie A.D., Smith C.A., Blackwood D.H., Muir W.J., Quinn J.P., Fink G., Goodwin G.M., and Harmar A.J. Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr. Genet. 6 (1996) 177-181
16. 108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1798-1805
17. Bhaduri N., Das M., Sinha S., Chattopadhyay A., Gangopadhyay P.K., Chaudhuri K., Singh M., and Mukhopadhyay K. Association of dopamine D4 receptor (DRD4) polymorphisms with attention deficit hyperactivity disorder in Indian population. Am. J. Hum. Genet. 141 (2006) 61-66
18. Black G.C., Chen Z.Y., Craig I.W., and Powell J.F. Dinucleotide repeat polymorphism at the MAOA locus. Nucleic Acid Res. 19 (1991) 689
19. Bray N.J., Buckland P.R., Hall H., Owen M.J., and O'Donovan M.C. The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol. Psychiatry 9 (2004) 109-114
20. Bray N.J., Buckland P.R., Williams N.M., Williams H.J., Norton N., Owen M.J., and O'Donovan M.C. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 73 (2003) 152-161
21. Brookes K.J., Mill J., Guindalini C., Curran S., Xu X., Knight J., Chen C.K., Huang Y.S., Sethna V., and Taylor E. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol pregnancy. Arch. Gen. Psychiatry 63 (2006) 74-81
22. Brookes K.J., Neale B.M., Sugden K., Khan N., Asherson A., and D'Souza U.M. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am. J. Med. Genet B Neuropsychiatr. Genet. 144B (2007) 1070-1078
23. Brookes K.J., Xu X., Chen C.-K., Huang Y.-S., Wu Y.-Y., and Asherson P. No evidence for the association of DRD4 with ADHD in a Taiwanese population within-family study. BMC Med. Genet. 6 (2005) 31
24. Brunner H.G., Nelen M., Breakefield X.O., Ropers H.H., and van Oost B.A. Abnormal behaviour associated with a point mutation in the structural gene for monoamine oxidase A. Science 262 (1993) 578-580
25. Cases O., Seif I., Grimsby J., Gaspar P., Chen K., Pournin S., Muller U., Aguet M., Babinet C., Shih J.C., et al. Aggressive behaviour and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 270 (1995) 362-364
26. Caspi A., McClay J., Moffitt T.E., Mill J., Martin J., Craig I.W., Taylor A., and Poulton R. Role of genotype in the cycle of violence in maltreated children. Science 297 (2002) 851-854
27. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol. Psychiatry 57 (2005) 1117-1127
28. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithewaite A., and Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
29. Catalano M. Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism. Eur. Neuropsychopharmacol. 11 (2001) 431-439
30. Chen C.-K., Chen S.-L., Mill J., Huang Y.-S., Lin S.-K., Curran S., Purcell S., Sham P., and Asherson P. The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol. Psychiatry 8 (2003) 393-396
31. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., and Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein and enzyme activity in post-mortem human brain. Am. J. Hum. Genet. 75 (2004) 807-821
32. Chen Z.-Y., Jing D., Bath K.G., Ieraci A., Khan T., Siao C.-J., Herrera D.G., Toth M., Yang C., McEwen B.S., Hempstead B.L., and Lee F.S. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behaviour. Science 314 (2006) 140-143
33. Chen Z.-Y., Patel P.D., Sant G., Meng C.-X., Teng K.K., Hempstead B.L., and Lee F.S. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 24 (2004) 4401-4411
34. Collier D.A., Arranz M.J., Sham P., Battersby S., Vallada H., Gill P., Aitchison K.J., Sodhi M., Li T., Roberts G.W., Smith B., Morton J., Murray R.M., Smith D., and Kirov G. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 7 (1996) 1675-1679
35. Cook E.H., Stein M.A., Krasowki M.D., Cox N.J., Olkon D.M., Kieffer J.E., and Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56 (1995) 993-998
36. Craddock N., Owen M.J., and O'Donovan M.C. The catechol-O-methyltransferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol. Psychiatry 11 (2006) 446-458
37. Craig I.W. The role of monoamine oxidase A, MAOA, in the aetiology of antisocial behaviour; the importance of gene environment interactions. Novartis Found. Symp. 268 (2005) 227-237
38. Craig I.W. The importance of stress and genetic variation in human aggression. Bioessays 29 (2007) 227-236
39. 3 receptor gene. J. Med. Genet. 29 (1992) 858-860
40. Curran S., Mill J., Tahir E., Kent L., Richards S., Gould A., Huckett L., Sharp J., Batten C., Fernando S., Ozbay F., Yazgan Y., Simonoff E., Thompson M., Taylor E., and Asherson P. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol. Psychiatry 6 (2001) 425-428
41. Dahmen N., Volp M., Singer P., Hiemke C., and Szegedi A. Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism. Psychiatr. Genet. 15 (2005) 13-16
42. Daly G., Hawi Z., Fitzgerald M., and Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT, DBH and DRD5 to affected children. Mol. Psychiatry 4 (1999) 192-196
43. Deckert J., Catalano M., Syagailo Y.V., Bosi M., Okladnova O., Di Bella D., Nothen M.M., Maffei P., Franke P., Fritze J., Maier W., Propping P., Beckmann H., Bellodi L., and Lesch K.-P. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 8 (1999) 621-624
44. Delbruck S.J., Wendel B., Grunewald I., Sander T., Morris-Rosendahl D., Crocq M.A., Berrettini W.H., and Hoehe M.R. A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. Cytogenet. Cell Genet. 79 (1997) 214-220
45. Dempster E.L., Mill J., Craig I.W., and Collier D.A. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med. Genet. 7 (2006) 10
46. Denney R.M., Koch H., and Craig I.W. Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat. Hum. Genet. 105 (1999) 542-551
47. Denney R.M., Sharma A., Dave S.K., and Waguespack A. A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression. J. Neurochem. 63 (1994) 843-856
48. Dick D.M., Plunkett J., Hamlin D., Nurnberger Jr. J., Kuperman S., Schuckit M., Hesselbrock V., Edenberg H., and Bierut L. Association analyses of the serotonin transporter gene with lifetime depression and alcohol dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) sample. Psychiatr. Genet. 17 (2007) 35-38
49. Ding Y.C., Chi H.C., Grady D.L., Morishima A., Kidd J.R., Kidd K.K., Flodman P., Spence M.A., Schuck S., Swanson J.M., and Moyzis R.K. Evidence of positive selection acting at the human dopamine receptor D4 gene locus. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 309-314
50. D'Souza U.M., and Craig I.W. Functional polymorphisms in dopamine and serotonin pathway genes. Hum. Mutat. 27 (2006) 1-13
51. D'Souza U.M., Russ C., Tahir E., Mill J., McGuffin P., Asherson P.J., and Craig I.W. Functional effects of a tandem duplication polymorphism in the 5′flanking region of the DRD4 gene. Biol. Psychiatry 56 (2004) 691-697
52. Dubertret C., Gorwood P., Ades J., Feingold J., Schwartz J.-C., and Sokoloff P. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am. J. Med. Genet. B Neuropsychiatr. Genet. 81B (1998) 318-322
53. 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6917-6922
54. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., and Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 (2003) 257-269
55. Eley T.C., Sugden K., Corsico A., Gregory A.M., Sham P., McGuffin P., Plomin R., and Craig I.W. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol. Psychiatry 9 (2004) 908-915
56. Ellingrod V.L., Lund B.C., Perry P.J., Bever-Stille K., Fleming F., Holman T.L., and Miller D. 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol. Bull. 37 (2003) 109-112
57. 4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry 156 (1999) 768-770
58. 4 receptor gene and attention deficit hyperactivity disorder. Am. J. Psychiatry 158 (2001) 1052-1057
59. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., and Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1313-1323
60. Fiskerstrand C.E., Lovejoy E.A., and Quinn J.P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 458 (1999) 171-174
61. Foley D.L., Eaves L.J., Wormley B., Silberg J.L., Maes H.H., et al. Childhood adversity, monoamine oxidase A genotype, and risk for conduct disorder. Arch. Gen. Psychiatry 61 (2004) 738-744
62. Frodl T., Meisenzahl E.M., Zill P., Baghai T., Rujescu D., Leinsinger G., Bottlender R., Schule C., Zwanzger P., Engel R.R., Rupprecht R., Bondy B., Reiser M., and Moller H.J. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch. Gen. Psychiatry 61 (2004) 177-183
63. Fowler J.S., Alia-Klein N., Kriplani A., Logan J., Williams B., Zhu W., Craig I.W., Telang F., Goldstein R., Volkow N.D., Vaska P., and Wang G.-W. Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol. Psychiatry 62 (2007) 355-358
64. Fuke S., Sasagawa N., and Ishiura S. Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3′non-coding polymorphic region of the human dopamine transporter (DAT1) gene. J. Biochem. 137 (2005) 205-216
65. Fuke S., Suo S., Takahashi N., Koike H., Sasagawa N., and Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 1 (2001) 152-156
66. Gill M., Daly G., Heron S., Hawi Z., and Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry 2 (1997) 311-313
67. Gillespie N.A., Whitfield J.B., Williams B., Heath A.C., and Martin N.G. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol. Med. 35 (2005) 101-111
68. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., Goldman D., and Weinberger D.R. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60 (2003) 889-896
69. Gornick M.C., Addington A., Shaw P., Bobb A.J., Sharp W., Greenstein D., Arepalli S., Castellanos F.X., and Rapoport J.C. Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyperactivity disorder (ADHD): an update. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 379-382
70. Green E.K., Raybould R., Macgregor S., Hyde S., Young A.H., O'Donovan M.C., Owen M.J., Kirov G., Jones L., Jones I., and Craddock N. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br. J. Psychiatry 188 (2006) 21-25
71. Greenwood T.A., and Kelsoe J.R. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82 (2003) 511-519
72. Guindalini C., Howard M., Haddley K., Laranjeira R., Collier D., Ammar N., Craig I., O'Gara C., Bubb V.J., Greenwood T., et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 4552-4557
73. Haberstick B.C., Lessem J.M., Hopfer C.J., Smolen A., Ehringer M.A., Timberlake D., and Hewitt J.K. Monoamine oxidase A (MAOA) and antisocial behaviors in the presence of childhood and adolescent maltreatment. Am. J. Med. Genet. B Neuropsychiatr. Genet. 135 (2005) 59-64
74. Hariri A., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., and Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science 297 (2002) 400-403
75. 66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 23 (2003) 6690-6694
76. Harvey L., Reid R.E., Caixia M., Knight P.J.K., Pfeifer T.A., and Grigliatti T.A. Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine. Pharmacogenetics 13 (2003) 107-118
77. Heils A., Teufel A., Petri S., Seemann M., Bengel D., Balling U., Riederer P., and Lesch K.-P. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J. Neural Transm. Gen. Sect. 102 (1995) 247-254
78. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., and Lesch K.P. Allelic variation of human serotonin transporter. J. Neurochem. 66 (1996) 2621-2624
79. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., Lee K.S., Linnoila M., and Weinberger D.R. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22 (2000) 133-139
80. Heinz A., Jones D.W., Mazzanti C., Goldman D., Ragan P., Hommer D., Linnoila M., and Weinberger D.R. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol. Psychiatry 47 (2000) 643-649
81. Hinds H.L., Hendriks R.W., Craig I.W., and Chen Z.Y. Characterization of a highly polymorphic region near the first exon of the human MAOA gene containing a GT dinucleotide and a novel VNTR motif. Genomics 13 (1992) 896-897
82. 4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol. Psychiatry 5 (2000) 523-530
83. Hong S.J., Huh Y., Chae H., Hong S., Lardaro T., and Kim K.S. GATA-3 regulates the transcriptional activity of tyrosine hydroxylase by interacting with CREB. J. Neurochem. 98 (2006) 773-781
84. Hotamisligil G.S., and Breakefield X.O. Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 49 (1991) 383-392
85. Hranilovic D., Stefulj J., Furac I., Kubat M., Balija M., and Jernej B. Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphism in Croatian suicide victims. Biol. Psychiatry 54 (2003) 884-889
86. Hranilovic D., Stefulj J., Schwab S., Borrmann-Hassenbach M., Albus M., Jernej B., and Wildenauer D. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry 55 (2004) 1090-1094
87. Hrdina P.D., and Du L. Levels of serotonin receptor 2A higher in suicide victims?. Am. J. Psychiatry 158 (2001) 147-148
88. Hu X., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., and Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78 (2006) 815-826
89. Huizinga D., Haberstick B.C., Smolen A., Menard S., Young S.E., Corley R.P., Stallings M.C., Grotpeter J., and Hewitt J.K. Childhood maltreatment, subsequent antisocial behavior, and the role of monoamine oxidase A genotype. Biol. Psychiatry 60 (2006) 677-683
90. Hwang J.P., Tsai S.J., Hong C.J., Yang C.H., Lirng J.F., and Yang Y.M. The Val66Met polymorphism of the brain derived neurotrophic factor gene is associated with geriatric depression. Neurobiol. Aging 27 (2006) 1834-1837
91. Iga J., Shu-Ichi U., Yamauchi K., Numata S., Tayoshi-Shibuya S., Kinouchi S., Nakataki M., Song H., Hokoishi K., Tanabe H., Sano A., and Ohmori T. The val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 1003-1006
92. Inoue-Murayama M., Adachi S., Mishima N., Mitani H., Takenaka O., Terao K., Hayasaka I., Ito S., and Murayama Y. Variation of variable number of tandem repeat sequences in the 3′-untranslated region of primate dopamine transporter genes that affects reporter gene expression. Neurosci. Lett. 334 (2002) 206-210
93. Inoue-Murayama M., Mishima N., Hayasaka I., Ito S., and Murayama Y. Divergence of ape and human monoamine oxidase A gene promoters: comparative analysis of polymorphisms, tandem repeat structures and transcriptional activities on reporter gene expression. Neurosci. Lett. 405 (2006) 207-211
94. Ishiguro H., Arinami T., Saito T., Akazawa S., Enomoto M., Mitushio H., Fujishiro H., Tada K., Akimoto Y., Mifune H., Shiozuka S., Hamaguchi H., Toru M., and Shibuya H. Systematic search for variations in the tyrosine hydroxylase gene and their associations with schizophrenia, affective disorders, and alcoholism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 81B (1998) 388-396
95. Jacobsen L.K., Staley J.K., Zoghbi S.S., Seibyl J.P., Kosten T.R., Innis R.B., and Gelernter J. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am. J. Psychiatry 157 (2000) 1700-1703
96. Jeong H., Kim M.S., Kwon J., Kim K.S., and Seol W. Regulation of the transcriptional activity of the tyrosine hydroxylase gene by androgen receptor. Neurosci. Lett. 396 (2006) 57-61
97. Jiang X., Xu K., Hoberman J., Tian F., Marko A.J., Waheed J.F., Harris C.R., Marini A.M., Enoch M.A., and Lipsky R.H. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30 (2005) 1353-1361
98. Jonsson E.G., Kaiser R., Brockmoller J., Vishwajit L., Nimgaonkar L., and Crocq M.-A. Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr. Genet. 14 (2004) 9-12
99. Kaiser R., Muller-Oerlinghausen B., Filler D., Tremblay P.-B., Berghofer A., Roots I., and Brockmoller J. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am. J. Med. Genet. B Neuropsychiatr. Genet. 114B (2002) 323-328
100. Kamakura S., Iwaki A., Matsumoto M., and Fukumaki Y. Cloning and characterisation of the 5′ flanking region of the human dopamine D4 receptor gene. Biochem. Biophys. Res. Commun. 235 (1997) 321-326
101. Kaufman J., Yang B.-Z., Douglas-Palumberi H., Houshyar S., Lipschitz D., Krystal J.H., and Gerlenter J. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 17316-17321
102. Kazmi M.A., Snyder L.A., Cypess A.M., Graber S.G., and Sakmar T.P. Selective reconstitution of human D4 dopamine receptor variants with Gia subtypes. Biochemistry 39 (2000) 3734-3744
103. Kendler K.S., Kuhn J.W., Vittum J., Prescott C.A., and Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch. Gen. Psychiatry 62 (2005) 529-535
104. Kereszturi E., Kiraly O., Barta C., Molnar N., Sasvari-Szekely M., and Csapo Z. No direct effect of the -521 C/T polymorphism in the human dopamine D4 receptor gene promoter on transcriptional activity. BMC Mol. Biol. 7 (2006) 18
105. Kereszturi E., Tarnok Z., Nemoda Z., Gadoros J., Kiraly O., Csapo Z., and Sasvari-Szekely M. Association between the 120-bp duplication of the dopamine D4 receptor gene and attention deficit hyperactivity disorder: genetic and molecular analyses. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 231-236
106. Kim-Cohen J., Newcombe R., Williams B., Moffitt T.E., Caspi A., Taylor A., and Craig I.W. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol. Psychiatry 11 (2006) 903-913
107. Klenova E., Scott A.C., Roberts J., Shamsuddin S., Lovejoy E.A., Bergmann S., Bubb V.J., Royer H.-D., and Quinn J.P. YB-1 and CTCF differentially regulate the 5-HTT polymorphic intron 2 enhancer which predisposes to a variety of neurological disorders. J. Neurosci. 24 (2004) 5966-5973
108. Kotler M., Barak P., Cohen H., Averbuch I.E., Grinshpoon A., Gritsenko I., Nemanov L., and Ebstein R. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol-O-methytransferase (COMT) activity. Am. J. Med. Genet. 88 (1999) 628-633
109. Kouzmenko A.P., Hayes W.L., Pereira A.M., Dean B., Burnet P.W.J., and Harrison P.J. 5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet 349 (1997) 1815
110. Kouzmenko A.P., Scaffidi A., Pereira A.M., Hayes W.L., Copolov D.L., and Dean B. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum. Hered. 49 (1999) 103-105
111. Kuersten S., and Goodwin E.B. The power of the 3′UTR: translational control and development. Nat. Rev. Genet. 4 (2003) 626-637
112. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., Hirose T., and Nanko S. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 2 (1997) 457-462
113. Kustanovich V., Ishii J., Crawford L., Yang M., McGough J.J., McCracken J.T., Smalley S.L., and Nelson S.F. Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. Mol. Psychiatry 9 (2004) 711-717
114. Lachman H.M., Nolan K.A., Mohr P., Saito T., and Volavka J. Association between catechol-O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 155 (1998) 835-837
115. LaHoste G.J., Swanson J.M., Wigal S.B., Glabe C., Wigal T., King N., and Kennedy J.L. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry 1 (1996) 121-124
116. 3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genet. 2 (1992) 249-256
117. Lesch K.-P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., and Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
118. Li D., Sham P.C., Owen M.J., and He L. Meta-analysis shows significant association between dopamine system and attention deficit hyperactivity disorder (ADHD). Hum. Mol. Genet. 15 (2006) 2276-2284
119. Li T., Chen C.-K., Hu X., Ball D., Lin S.-K., Chen W., Sham P.C., Loh E.-W., Murray R.M., and Collier D.A. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am. J. Med. Genet. 129 (2004) 120-124
120. Li T., Sham P.C., Vallada H., Xie T., Tang X., Murray R.M., Liu X., and Collier D.A. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr. Genet. 6 (1996) 131-133
121. Litcher J.B., Barr C.L., Kennedy J.L., Van Tol H.H., Kidd K.K., and Livak K.J. A hypervariable segment in the human dopamine D4 (DRD4) gene. Hum. Mol. Genet. 2 (1993) 767-773
122. Little K.Y., McLaughlin D.P., Zhang L., Livermore C.S., Dalack G.W., McFinton P.R., DelProposto Z.S., Hill E., Cassin B.J., Watson S.J., and Cook E.H. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am. J. Psychiatry 155 (1998) 207-213
123. Lohoff F.W., Sander T., Ferraro T.N., Dahl J.P., and Berrettini W.H. Confirmation of association between the Val66Met polymorphism in the brain derived neurotrophic factor (BNF) gene and bipolar 1 disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139B (2005) 51-53
124. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., and Taskinen J. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34 (1995) 4202-4210
125. Lovejoy E.A., Scott A.C., Fiskerstrand C.E., Bubb V.J., and Quinn J.P. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur. J. Neurosci. 17 (2003) 417-420
126. Lüdecke B., and Bartholomé K. Frequent sequence variant in the human tyrosine hydroxylase gene. Hum. Genet. 95 (1995) 716
127. 3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun. 225 (1996) 1068-1072
128. MacKenzie A., and Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15251-15255
129. Mann J.J., Huang Y.-Y., Underwood M., Kassir S.A., Oppenheim S., Kelly T.M., Dwork A.J., and Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry 57 (2000) 729-738
130. 3 receptor gene and schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 54B (1994) 21-26
131. Martin J., Cleak J., Willis-Owen S.A., Flint J., and Shifman S. Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. Mol. Psychiatry 12 (2007) 421-422
132. Martinez D., Gelernter J., Abi-Dargham A., van Dyck C.H., Kegeles L., Innis R.B., and Laruelle M. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24 (2001) 553-560
133. 158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6186-6191
134. McAllister T.W., and Summerall L. Genetic polymorphisms in the expression and treatment of neuropsychiatric disorders. Curr. Psychiatry Rep. 5 (2003) 400-409
135. McCracken J.T., Smalley S.L., McGough J.J., Crawford L., Del'Homme M., Cantor R.M., Liu A., and Nelson S.F. Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). Mol. Psychiatry 5 (2000) 531-536
136. Meloni R., Albanese V., Ravassard P., Treilhou F., and Mallet J. A tetranucleotide polymorphic microsatellite, located in the first intron of the tyrosine hydroxylase gene, acts as a transcription regulatory element in vitro. Hum. Mol. Genet. 7 (1998) 423-428
137. Meloni R., Laurent C., Campion D., Ben Hadjali B., Thibaut F., Dollfus S., Petit M., Samolyk D., Martinez M., Poirier M.-F., and Mallet J. A rare allele of a microsatellite located in the tyrosine hydroxylase gene found in schizophrenic patients. C.R. Acad. Sci. III 318 (1995) 803-809
138. Meloni R., Sauty C., Mallet J., and Faucon Biguet N. The polymorphic (TCAT)N sequence of the HUMTH01 microsatellite in the tyrosine hydroxylase gene and the regulation of gene expression. J. Psychopharmacol. 21 (2007) S23
139. Messmer K., Remington M.P., Skidmore F., and Fishman P.S. Induction of tyrosine hydroxylase expression by the transcription factor Pitx3. Int. J. Dev. Neurosci. 25 (2007) 29-37
140. Michaelovsky E., Frisch A., Rockah R., Peleg L., Magal N., Shohat M., and Weizman R. A novel allele in the promoter region of the human serotonin transporter gene. Mol. Psychiatry 4 (1999) 97-99
141. Michelhaugh S.K., Fiskerstrand C., Lovejoy E., Bannon M.J., and Quinn J.P. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J. Neurochem. 79 (2001) 1033-1038
142. Mignone F., Gissi C., Liuni S., and Pesole G. Untranslated regions of mRNAs. Genome Biol. 3 (2002) reviews, 0004.1-0004.10.
143. Mill J., Asherson P., Browes C., D'Souza U., and Craig I. Expression of the dopamine transporter gene is regulated by the 3′UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am. J. Med. Genet. B Neuropsychiatr. Genet. 114B (2002) 975-979
144. Mill J., Asherson P., Craig I., and D'Souza U.M. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet. 6 (2005) 3
145. 4 receptor gene: evidence of association but no linkage in a UK sample. Mol. Psychiatry 6 (2001) 40-44
146. Mill J., Fischer N., Curran S., Richards S., Taylor E., and Asherson P. Polymorphisms in the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Neuroreport 14 (2003) 1463-1466
147. Miller G.M., and Madras B.K. Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 7 (2002) 44-55
148. Monteleone P., Zanardini R., Tortorella A., Gennarelli M., Castaldo E., Canestrelli B., and Maj M. The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neurosci. Lett. 406 (2006) 133-137
149. Mossner R., Daniel S., Albert D., Heils A., Okladnova O., Schmitt A., and Lesch K.-P. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem. Int. 36 (2000) 197-202
150. Myers R.L., Airey D.C., Manier D.H., Shelton R.C., and Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol. Psychiatry 61 (2007) 167-173
151. Nakamura M., Ueno S., Sano A., and Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry 5 (2000) 32-38
152. Naylor L., Dean B., Pereira A., Mackinnon A., Kouzmenko A., and Copolov D. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Mol. Med. 4 (1998) 671-674
153. Neves-Pereira M., Mundo E., Muglia P., King N., Macciardi F., and Kennedy J.L. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am. J. Hum. Genet. 71 (2002) 651-655
154. Nilsson K.W., Sjoberg R.L., Damberg M., Leppert J., Ohrvik J., et al. Role of monoamine oxidase A genotype and psychosocial factors in male adolescent criminal activity. Biol. Psychiatry 59 (2006) 121-127
155. Nilsson K.W., Sjoberg R.L., Wargelius H.L., Leppert J., Lindstrom L., and Oreland L. The monoamine oxidase A (MAO-A) gene, family function and maltreatment as predictors of destructive behaviour during male adolescent alcohol consumption. Addiction 102 (2007) 389-398
156. Ogilvie A.D., Battersby S., Bubb V.J., Fink G., Harmar A.J., Goodwin G., and Smith C.A. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347 (1996) 731-733
157. Okada T., Hashimoto R., Numakawa T., Iijima Y., Kosuga A., Tatsumi M., Kamijima K., Kato T., and Kunugi H. A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol. Psychiatry 11 (2006) 695-703
158. Okuyama Y., Ishiguro H., Nankai M., Shibuya H., Watanabe A., and Arinami T. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol. Psychiatry 5 (2000) 64-69
159. Oswald L.M., McCaul M., Choi L., Yang X., and Wand G.S. Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Biol. Psychiatry 55 (2004) 102-105
160. Ou X.M., Chen K., and Shih J.C. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J. Biol. Chem. 281 (2006) 21512-21525
161. Parsons M.J., D'Souza U.M., Arranz M.J., Kerwin R.W., and Makoff A.J. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 56 (2004) 406-410
162. Peng C., Fan S., Li X., Fan X., Ming M., Sun Z., and Le W. Overexpression of pitx3 upregulates expression of BDNF and GDNF in SH-SY5Y cells and primary ventral mesencephalic cultures. FEBS Lett. 581 (2007) 1357-1361
163. Pinsonneault J.K., Papp A.C., and Sandee W. Allelic mRNA expression of X-linked monoamine oxidase (MAOA) in human brain: dissection of epigenetic and genetic factors. Hum. Mol. Genet. 15 (2006) 2636-2649
164. Polesskaya O.O., and Sokolov B.P. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 67 (2002) 812-822
165. Polymeropoulos M., Xiao H., Rath D., and Merril C. Tetranucleotide repeat polymorphism at the human tyrosine hydroxylase gene (TH). Nucleic Acids Res. 19 (1991) 3753
166. Pruunsild P., Kazantseva A., Aid T., Palm K., and Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90 (2007) 397-406
167. Roberts J., Scott A.C., Howard M.R., Breen G., Bubb V.J., Klenova E., and Quinn J.P. Differential regulation of the serotonin transporter gene by lithium is mediated by transcription factors, CCCTC binding protein and Y-box binding protein 1, through the polymorphic intron 2 variable number tandem repeat. J. Neurosci. 27 (2007) 2793-2801
168. Rogers G., Joyce P., Mulder R., Sellman D., Miller A., Allington M., Robin O., Wells E., and Kennedy M. Association of a duplicated repeat polymorphism in the 5′-untranslated region of the DRD4 gene with novelty seeking. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126B (2004) 95-98
169. Romano G., Macaluso M., Lucchetti C., and Iacovitti L. Transcription and epigenetic profile of the promoter, first exon and first intron of the human tyrosine hydroxylase gene. J. Cell. Physiol. 211 (2007) 431-438
170. Rowe D.C., Stever C., Giedinghagen L.N., Gard J.M.C., Cleveland H.H., Terris S.T., Mohr J.H., Sherman S., Abramowitz A., and Waldman I.D. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol. Psychiatry 3 (1998) 419-426
171. Rujescu D., Giegling I., Gietl A., Hartmann A.M., and Moller H.-J. A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. Biol. Psychiatry 54 (2003) 34-39
172. Sabol S.Z., Hu S., and Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103 (1998) 273-279
173. Scharfman H.E., and MacLusky N.J. Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front. Neuroendocrinol. 27 (2006) 415-435
174. Schumacher J., Jamra R.A., Becker T., Ohlraun S., Klopp N., Binder E.B., Schulze T.G., Deschner M., Schmal C., Hofels S., Zobel A., Illig T., Propping P., Holsboer F., Rietschel M., Nothen M.M., and Cichon S. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol. Psychiatry 58 (2005) 307-314
175. Seaman M.I., Fischer J.B., Chang F.-M., and Kidd K.K. Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4). Am. J. Med. Genet. B Neuropsychiatr. Genet. 88B (1999) 705-709
176. Sen S., Nesse R.M., Stoltenberg S.F., Li S., Gleiberman L., Chakravarti A., Weder A.B., and Burmeister M. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 28 (2003) 397-401
177. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weizman A., Reznik I., Spivak B., Grisaru N., Karp L., Schiffer R., Kotler M., Strous R.D., Swartz-Vanetik M., Knobler H.Y., Shinar E., Beckmann J.S., Yakir B., Risch N., Zak N.B., and Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 71 (2002) 1296-1302
178. Sklar P., Gabriel S.B., McInnis M.G., Bennett P., Lim Y.-M., Tsan G., Schaffner S., Kirov G., Jones I., Owen M., Craddock N., DePaulo J.R., and Lander E.S. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol. Psychiatry 7 (2002) 579-593
179. 4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Mol. Psychiatry 3 (1998) 427-430
180. Smiths K.M., Smiths L.J.M., Schouten J.S.A.G., Stelma F.F., Nelemans P., and Prins M.H. Influence of SERTPR and Stin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry 9 (2004) 433-441
181. Sohrabji F., and Lewis D.K. Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front. Neuroendocrinol. 27 (2006) 404-414
182. Spurlock G., Heils A., Holmans P., Williams J., D'Souza U.M., Cardno A., Murphy K.C., Jones L., Buckland P.R., McGuffin P., Lesch K.P., and Owen M.J. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol. Psychiatry 3 (1998) 42-49
183. 9Gly polymorphisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 81B (1998) 24-28
184. Staddon S., Arranz M.J., Mancama D., Perez-Nievas F., Arrizabalaga I., Anney R., Buckland P., Elkin A., Osborne S., Munro J., Mata I., and Kerwin R. Association between dopamine D3 receptor polymorphisms and schizophrenia in an isolate population. Schizophr. Res. 73 (2005) 49-54
185. Strous R.D., Bark N., Parsia S.S., Volavka J., and Lachman H.M. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behaviour. Psychiatry Res. 69 (1997) 71-77
186. Strous R.D., Nolan K.A., Lapidus R., Diaz L., Saito T., and Lachman H.M. Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 1B (2003) 29-43
187. Surtees P.G., Wainwright N.W., Willis-Owen S.A., Sandhu M.S., Luben R., Day N.E., and Flint J. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. J. Psychiatr. Res. 41 (2007) 404-409
188. 4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol. Psychiatry 3 (1998) 38-41
189. Tahir E., Yazgan Y., Cirakoglu B., Ozbay F., Waldman I., and Asherson P.J. Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol. Psychiatry 5 (2000) 396-404
190. Tsai S.-J., Cheng C.-Y., Yu Y.W.-Y., Chen T.-J., and Hong C.-J. Association study of a brain-derived neurotrophic factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 123B (2003) 19-22
191. Turecki G., Briere R., Dewar K., Antonetti T., Lesage A.D., Seguin M., Chawky N., Vanier C., Alda M., Joober R., Benkelfat C., and Rouleau G.A. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatry 156 (1999) 1456-1458
192. Ueno S. Genetic polymorphisms of serotonin and dopamine transporters in mental disorders. J. Med. Invest. 50 (2003) 25-31
193. Vandenbergh D.J., Persico A.M., and Uhl G.R. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res. Mol. Brain Res. 15 (1992) 161-166
194. VanNess S.H., Owens M.J., and Kilts C.D. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 6 (2005) 55
195. Van Tol H.H.M., Wu C.M., Guan H.-C., Ohara K., Bunzow J.R., Civelli O., Kennedy J., Seeman P., Niznik H.B., and Jovanoic V. Multiple dopamine D4 receptor variants in the human population. Nature 358 (1992) 149-152
196. Waldman I.D., Rowe D.C., Abramowitz A., Kozel S.T., Mohr J.H., Sherman S.L., Cleveland H.H., Sanders M.L., Gard J.M.C., and Stever C. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. 63 (1998) 1767-1776
197. 2A promoter polymorphism -1438 G/A in children and adolescents with obsessive-compulsive disorders. Mol. Psychiatry 7 (2002) 1054-1057
198. 108/158Met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 56 (2004) 677-682
199. Wendland J.R., Hampe M., Newman T.K., Syagailo Y., Meyer J., Schempp W., Timme A., Suomi S.J., and Lesch K.P. Structural variation of the monoamine oxidase A gene promoter repeat polymorphism in non human primates. Genes Brain Behav. 5 (2005) 40-45
200. Wickens M., Bernstein D.S., Kimble J., and Parker R. A PUF family portrait: 3′UTR regulation as a way of life. Trends Genet. 18 (2002) 150-157
201. Wilhelm K., Mitchell P.B., Niven H., Finch A., Wedgwood L., Scimone A., Blair I.P., Parker G., and Schofield P.R. Life events, first depression onset and the serotonin transporter gene. Br. J. Psychiatry 188 (2006) 210-215
202. Willeit M., Stastny J., Pirker W., Praschak-Rieder N., Neumeister A., Asenbaum S., Tauscher J., Fuchs K., Sieghart W., Hornik K., Aschauer H.N., Brucke T., and Kasper S. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol. Psychiatry 50 (2001) 8-12
203. Williams H.J., Owen M.J., and O'Donovan M.C. Is COMPT a susceptibility gene for schizophrenia?. Schizophr. Bull. 33 (2007) 635-641
204. 3 receptor gene and schizophrenia. Mol. Psychiatry 3 (1998) 141-149
205. Williams J., Spurlock G., McGuffin P., Mallet J., Nothen M.M., Gill M., Aschauer H., Nylander P.O., Macciardi F., and Owen M.J. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 347 (1996) 1294-1296
206. Willis-Owen S.A.G., Fullerton J., Surtees P.G., Wainwright N.W.J., Miller S., and Flint J. The Val66Met coding variant of the brain derived neurotrophic factor (BDNF) does not contribute toward variation in the personality trait neuroticism. Biol. Psychiatry 58 (2005) 738-742
207. Wong A.H.C., Buckle C.E., and Van Tol H.H.M. Polymorphisms in dopamine receptors: what do they tell us?. Eur. J. Pharmacol. 410 (2000) 183-203
208. 4 receptor gene in schizophrenia. Schizophr. Res. 65 (2003) 9-14
209. Yang B., Chan R.C.K., Jing J., Li T., Sham P., and Chen R.Y.L. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3′UTR of dopamine transporter gene and attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 541-550
210. Young S.E., Smolen A., Hewitt J.K., Haberstick J.K., Brett C., et al. Interaction between MAOA genotype and maltreatment in the risk for conduct disorder: failure to confirm in adolescent patients. Am. J. Psychiatry 163 (2006) 951-953
211. Zarrin A.A., Malkin L., Fong I., Luk K.D., Ghose A., and Berinstein N.L. Comparison of CNV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochim. Biophys. Acta 1446 (1999) 135-139
212. Zhu G., Lipsky R.H., Xu K., Ali S., Hyde T., Kleinman J., Akhtar L.A., Mash D.C., and Goldman D. Differential expression of human COMT alleles in brain and lymphoblasts detected by RT-coupled 5′nuclease assay. Psychopharmacology (Berl.) 177 (2004) 178-184
213. Zhu Q.-S., Grimsby J., Chen K., and Shih J.C. Promoter organisation and activity of human monoamine oxidase (MAO) A and B genes. J. Neurosci. 12 (1992) 4437-4446
214. Zhu Q.-S., and Shih J.C. An extensive repeat structure down-regulates human monoamine oxidase A promoter activity independent of an initiator-like sequence. J. Neurochem. 69 (1997) 1368-1373